Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL12352425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL1821276 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4522263 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL13362239 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2228590 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL406207 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403819 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599817-A1 | IMPACT ON ENAMEL AND DENTINE HYPERSENSITIVITY THROUGH MEDIATED IMPACT OF ANTAGONISTS ON TRPV1 AND TRCP5 CHANNELS IN ORAL CARE PRODUCTS | SkyLab AG (CH) | 2025-08-13 | — | — | EP | claimed |
| CN-117815255-A | Combined medicine based on neuroprotection and p38MAPK inhibitor | 南京中医药大学 | 2024-04-05 | — | — | CN | claimed |
| CN-117815254-A | Combined medicine based on neuroprotection and p38MAPK pathway inhibitor | 南京中医药大学 | 2024-04-05 | — | — | CN | claimed |
| US-20130224239-A1 | ALCOHOLIC EXTRACT OF FUNGI OF GENUS CUNNINGHAMELLA AND USE THEREOF | KING SAUD UNIVERSITY (SA) | 2013-08-29 | — | — | US | claimed |
| EP-2497477-B1 | Use of a Cunninghamella alcoholic extract as antimicrobial | UNIV KING SAUD (SA) | 2013-08-07 | — | — | EP | claimed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| WO-2012119699-A1 | ALCOHOLIC EXTRACT OF FUNGI OF GENUS CUNNINGHAMELLA AND USE THEREOF | KING SAUD UNIVERSITY (SA) | 2012-09-13 | — | — | WO | claimed |
| EP-2497477-A1 | Alcoholic extract of fungi of genus Cunninghamella and use thereof | King Saud University (SA) | 2012-09-12 | — | — | EP | claimed |
| CN-119019837-B | Self-repairing material assembled by nucleobase pairs and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2026-05-12 | — | — | CN | disclosed |
| CN-122011852-A | Single-component acrylic asphalt rust-carrying coating anti-corrosive paint | 苏州大乘环保新材有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-12478570-B2 | Cosmetic formulation | FERNANDEZ VICTOR (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250288624-A1 | LONG-TERM STABILIZATION, FORMULATION AND TABLETING OF LIVE MICROBIAL CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250241836-A1 | Cosmetic Formulation | FERNANDEZ VICTOR (US) | 2025-07-31 | — | — | US | disclosed |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-23 | — | — | US | disclosed |
| US-20050032723-A1 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | PHARMAXIS LTD (AU) | 2005-02-10 | — | — | US | disclosed |
| EP-1406667-A2 | METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | Topigen Pharmaceutiques Inc (CA) | 2004-04-14 | — | — | EP | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| WO-2003004511-A2 | METHODS FOR INCREASING IN VIVO EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS | TOPIGEN PHARMACEUTIQUE INC.. (CA) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224239-A1 | ALCOHOLIC EXTRACT OF FUNGI OF GENUS CUNNINGHAMELLA AND USE THEREOF | ADH1C, ADH5, ERG28 | ADORA3 4308/4885ADORA2A 4557/4885ADORA2B 4532/4885 |
| US-20050137162-A1 | New COMT inhibitors for the treatment of depression and impaired cognition | COMT, MAOB, TPH1 | ADORA3 1333/4885ADORA2A 1244/4885ADORA2B 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.